Strengthening Africa Health Partnership

By Crystal Lubbe

February 20, 2025

The Africa health partnership between the Africa Centres for Disease Control and Prevention (Africa CDC) and the Global Health European & Developing Countries Clinical Trials Partnership 3 (Global Health EDCTP3) has resulted in a signed Memorandum of Understanding (MoU). Specifically, this agreement aims to enhance collaboration in health research, clinical trials, and pandemic preparedness across Africa.

Furthermore, the MoU includes a Joint Action Plan for 2025-2027, which focuses on six key areas of cooperation, such as strengthening the public health workforce, clinical trial ecosystems, and local manufacturing of health products. This partnership is crucial in addressing growing global health challenges, including climate change, conflicts, and limited public health funding.

Key Insights

  • Strengthening Health Workforce and Research Capacity: The MoU highlights the need for training and capacity building. This effort aims to enhance health research capabilities in sub-Saharan Africa.

  • Clinical Trials and Pandemic Preparedness: The agreement seeks to improve clinical trial ecosystems in African Union member states. It also advances research on new interventions for infectious diseases.

  • Local Manufacturing and Regulatory Frameworks: The partnership supports local production of vaccines, diagnostics, and treatments. Additionally, it strengthens regulatory pathways to ensure quality and safety.

  • Equitable Partnerships and Resource Mobilization: The MoU fosters action-driven, equitable partnerships. It also promotes resource mobilization by aligning priorities and leveraging public-private sector synergies.

Previous Collaborations and Challenges

The new MoU builds on a previous partnership established in 2021 between the EDCTP Association and Africa CDC, indicating a long-term commitment to collaborative health initiatives. This Africa health partnership addresses critical global health challenges, such as climate change, ongoing conflicts, and constrained financial resources for public health, which are significant concerns for public health agencies around the world. The initiative aligns with broader regional efforts, such as the Africa CDC Flagship Initiative on Health Data Governance, which aims to strengthen health data governance approaches across Africa.

Implications

The partnership is likely to yield positive implications for health economics in Africa by enhancing local manufacturing capabilities. This reduces reliance on external sources for vaccines and treatments, potentially lowering costs and leading to more sustainable public health solutions. By strengthening the health research workforce, clinical trial ecosystems, and pandemic preparedness, the partnership is expected to improve health outcomes across the continent. This includes better response mechanisms to infectious diseases and emerging health threats. Emphasising African-led solutions and local manufacturing is crucial for sustainable health innovations. This approach can lead to tailored and effective health interventions that are better suited to the specific needs of African populations.

The partnership between Africa CDC and Global Health EDCTP3 represents a significant step towards enhancing Africa’s health research, clinical trial capabilities, and pandemic preparedness. Ultimately, it aims to contribute to improved public health outcomes and sustainable health innovations in the region.

Reference url

Recent Posts

Strategic Avalere Health Appointments Enhance Leadership in Navigating US Healthcare Policy Changes

By João L. Carapinha

December 17, 2025

Avalere Health strengthened its appointments, with Matt Kazan returning as Senior Vice President of Policy, where he previously served as a former top advisor on the US Senate Committee on Finance, and he will now lead the policy team amid changes like the Inflation Reduction Act. Laura Housman, ...
Positive ARTISTRY-2 Trial Results for BIC LEN HIV Regimen
BIC/LEN HIV Regimen Delivers Non-Inferior Results in ARTISTRY-2 Gilead Sciences announced positive topline results from the Phase 3 ARTISTRY-2 trial, demonstrating that the investigational BIC LEN HIV regimen
AKEEGA BRCA2 Approval: Landmark FDA Decision for Precision Therapy in Aggressive Prostate Cancer

By HEOR Staff Writer

December 16, 2025

AKEEGA BRCA2 Approval Ushers in Precision Era for mCSPC The AKEEGA BRCA2 approval by the U.S. Food and Drug Administration (FDA) on December 12, 2025, represents a breakthrough for patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). Johnson & Johnson...